Blar i Institutt for klinisk og molekylær medisin på forfatter "Xu, S"
-
JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells
Xu, W; Chen, Q; Wang, Q; Sun, Y; Wang, S; Li, A; Xu, S; Røe, Oluf Dimitri; Wang, R; Zhang, R.; Yang, L; Zhou, J. (Journal article; Peer reviewed, 2014)Gastric cancer is the third most common malignancy in China, with a median 5-year survival of only 20%. Cisplatin has been used in first-line cancer treatment for several types of cancer including gastric cancer. However, ... -
TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer
Xu, W; Wang, S; Chen, Q; Zhang, Y; Ni, P; Wu, X; Zhang, J; Qiang, F; Li, A; Røe, Oluf Dimitri; Xu, S; Wang, M; Zhang, R.; Zhou, J. (Journal article; Peer reviewed, 2014)Cisplatin is a cytotoxic platinum compound that triggers DNA crosslinking induced cell death, and is one of the reference drugs used in the treatment of several types of human cancers including gastric cancer. However, ...